Products eligible for assessment under the ZaZiBoNa initiative consist of all essential medicines and medicines used in the treatment of the SADC priority diseases or conditions listed below:
|4||Acute respiratory infections|
|11||Gastroenteritis and colic|
|12||Reproductive health products|
|13||Products included in the list of United Nations Commission for Life-Saving Commodities for Women and Children Final UN Commission Report_14sept2012.pdf (unfpa.org)|
In addition to these other medicines that may be important from a public health perspective can also be considered.
The WHO-prequalified products (Prequalified Lists | WHO – Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)) are not eligible for consideration under ZaZiBoNa, as most SADC countries participate in the WHO prequalification collaborative registration procedure, in which countries rely on assessments and inspections conducted by the WHO prequalification team (PQT) enabling registration in 90 days after completion of the verification process. However, the WHO Stringent Regulatory Agencies (SRA) collaborative registration procedure (Accelerated Registration of FPPs Approved by SRAs | WHO – Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)) can be used to accelerate assessment of products already approved by globally recognized regulatory agencies; for example, the European Medicines Agency (EMA)